AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.

As reliever monotherapy for mild asthma, the inhaled corticosteroid (ICS)-formoterol combination reduced asthma attacks in children compared with a short-acting β₂-agonist (SABA), the CARE trial ...

SAN FRANCISCO (MarketWatch) -- AstraZeneca PLC said Monday that results from a one-year study show that patients taking its Symbicort single-inhaler therapy had fewer asthma attacks and required less ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated.

Starting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price caps go into effect for the asthma medications from AstraZeneca and Boehringer Ingelheim. Following ...

MADISON, Wis.--(BUSINESS WIRE)--Propeller Health, a leading digital health company dedicated to the management of asthma and COPD, today announced it has received 510(k) clearance from the U.S. Food ...

ATLANTA - Prices are rising sharply on many asthma inhalers just in time for spring allergy season and some insurance companies are not covering the higher costs, and many patients cannot afford the ...